Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial

Benzinga

By Meg Flippin, Benzinga Cognition Therapeutics Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders including dementia with Lewy bodies (DLB), announced positive topline results of its exploratory phase 2 SHIMMER study for CT1812, its experimental orally delivered small molecule oligomer antagonist to treat this progressive form of dementia. Cognition Therapeutics said the trial demonstrated CT1812 produced strong therapeutic responses across behavioral, functional, cognitive and movement measures in patients with DLB. DLB is a form of dementia in which symptoms come on fast. DLB can quickly lead to a decline in thinking and reasoning as well as independent movements, and can cause uncontrollable changes in alertness, recurring hallucinations, sleep disruptions, tremors and slow movement. It impacts about 1.4 million people in the U.S. and is the costliest form of dementia. As it stands, drugs to cure this debilitating form of dementia are nonexistent, and treatments, which are used off-label focus on managing symptoms. Promise In A Pill “These topline results exceeded our expectations and support the broad potential of CT1812 across neurodegenerative disorders,” Anthony Caggiano, M.D., Ph.D., Cognition’s chief medical officer and head of R&D, said when announcing the results. “Analysis of CT1812’s activity in DLB will continue as additional data become available. We look forward to reporting these findings at future medical meetings and reviewing them with the FDA in an end-of-phase 2 meeting.” The phase 2 SHIMMER study enrolled 130 adults who were randomized to receive either placebo or one of two oral once-daily doses of CT1812 (100 mg or 300 mg) for six months. Participants were assessed throughout the study using the Montreal Cognitive Assessment (MoCA) and Cognitive Drug Research (CDR) Battery, which track cognitive performance; the Clinician Assessment of Fluctuation (CAF) to measure the frequency and duration of cognitive fluctuations; and the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III, an objective assessment of parkinsonism. Cognition Therapeutics said the study met its primary endpoint of safety and tolerability, with data showing that DLB patients treated with CT1812 for six months experienced improvement in behavioral, functional, cognitive and movement measures compared to the placebo. Cognition reported an 82% slowing in the total neuropsychiatric inventory (NPI), with a particularly strong reduction in anxiety, hallucinations and delusions in the CT1812 treated arms. In addition, there was a marked reduction in caregiver distress, which suggests a positive impact on the day-to-day lives of those receiving the drug, reports the company. Participants treated with CT1812 experienced a slowing of decline across all three cognitive measures compared to the placebo, including fluctuations in attention which declined by 91%. Cognition plans to present detailed data at the International Lewy Body Dementia Conference (ILBDC) in January 2025. The SHIMMER study is supported by a grant award from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million and is being conducted in collaboration with the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and the Lewy Body Dementia Association (LBDA). Preceding Trial Had Promising Results Cognition had previously completed a Phase 2 SHINE study to look at CT1812’s effects on treating individuals aged 50 to 85 who have mild-to-moderate Alzheimer’s disease. That study recruited 153 individuals, and the results showed a 95% slowing of cognitive decline in people exhibiting a key Alzheimer’s disease biomarker. “With the SHIMMER and SHINE results, we are confident in CT1812’s clinical activity given that it has demonstrated broad neurologic and neuroprotective activity in DLB and Alzheimer’s disease,” Lisa Ricciardi, Cognition’s president and CEO, said. “People with these diseases, particularly DLB, have few therapeutic options leading to a cascade of symptoms that are painful to the individual and their caregivers. We are eager to continue the development of CT1812 in late-stage clinical trials with the hope of providing a once-daily pill that can treat these devastating neurodegenerative conditions.” To learn more about Cognition Therapeutics and its SHIMMER study, click here. Featured photo by Rad Cyrus on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 20, 2024 08:35 AM Eastern Standard Time

Image

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Benzinga

By Meg Flippin, Benzinga Mainz Biomed N.V. (NASDAQ: MYNZ), the molecular genetics diagnostic company specializing in the early detection of cancer, is moving closer to commercializing its early colorectal cancer detection screening ColoAlert® in the U.S. by inking deals with Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services. As part of the agreements, Mainz Biomed said Quest Diagnostics will provide clinical trial and laboratory services to support its ReconAAsense Food and Drug Administration pivotal study of ColoAlert. The clinical trial is slated to kick off next year with up to 15,000 patients. If ColoAlert gets the nod from the U.S. FDA, it will be able to target the millions of Americans at risk of colorectal cancer. Mainz has said its commercial strategy is to establish scalable distribution in the U.S. through a collaborative partner program with regional and national laboratory service providers. The recent strategic alliance with Thermo Fisher Scientific (NYSE: TMO), a global leader in life sciences with annual revenue exceeding $40 billion, represents a monumental step forward in transforming cancer prevention in the United States, says Mainz. This partnership harnesses Thermo Fisher's extensive expertise and state-of-the-art infrastructure to drive innovation in healthcare solutions. Adding further depth to this initiative is the collaboration with Quest Diagnostics, a leader in advanced testing and sampling technologies. Quest Diagnostics offers a broad range of services, including routine blood work, genetic and molecular testing and specialized diagnostic services for various diseases, such as cancer, cardiovascular conditions and infectious diseases. Mainz reports that Quest Diagnostics is widely recognized for its national network of laboratories, extensive patient service centers and cutting-edge technology that ensures accurate and timely test results. As a significant player in the healthcare industry, particularly in diagnostic testing and sampling, Quest Diagnostics serves millions of patients and healthcare providers annually, making it a critical component in advancing precision and scalability in early cancer detection and prevention. With $8 million in funding dedicated to expediting FDA approval, this initiative aims to rapidly advance critical milestones, laying the groundwork for massive expansion. Together, Mainz believes these partnerships are poised to catalyze a sweeping transformation in public health outcomes, creating a tidal wave of innovation and economic growth that will ripple across the healthcare landscape. Readying ColoAlert For Potential U.S. Debut In addition to supporting the clinical trial, Mainz said Quest Diagnostics has a semi-exclusive right to market ColoAlert in the U.S. for an eighteen-month period. If exercised, this option will allow Quest Diagnostics the opportunity to offer the product to multiple channels, including physicians, health systems, hospitals, health plans, employers and consumers, reports Mainz Biomed. “We are excited by the opportunity to collaborate with Quest Diagnostics,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Teaming with Quest Diagnostics during our critical FDA Study will be key to our long-term success.” Encouraging Trial Results ColoAlert is an early detection screening that spots bleeding and non-bleeding tumors through tumor DNA analysis. ColoAlert analyzes samples for the four tumor markers associated with cancer: KRAS-mutation, BRAF-mutation, total amount of human DNA and occult blood. By analyzing tumor DNA, Mainz says ColoAlert detects 85% of colorectal cancer cases, often in the very early stages of the disease. Based on recent trials, Mainz Biomed says ColoAlert’s sensitivities exceeded 90% for detecting colorectal cancer and over 80% for advanced adenomas. Detecting advanced adenomas is crucial in preventing colorectal cancer, as identifying patients with these lesions allows for timely intervention through colonoscopy and adenoma removal, thereby averting cancer development, reports Mainz. Big Addressable Market It's a big market for Mainz Biomed to address, given colorectal cancer is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The U.S. Preventive Services Task Force recommends that screening with stool DNA tests be conducted once every three years, starting at age 45. As it stands, 71% of the diagnoses made are in the later stages of the disease. But if it's caught early, the survival rate after five years is 90%. Despite those favorable odds, only about four in ten colorectal cancers are spotted at the early stage. Each year in the U.S., 16.6 million colonoscopies are performed, yet about one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4 billion total market opportunity in the U.S., according to estimates compiled by Mainz Biomed. ColoAlert, if approved in the U.S., may help rectify that lack of timely screening. After all, Mainz Biomed says its detection system is less invasive than ColoGuard, the leading at-home test in the U.S., because it requires very small samples to test. It’s one of the reasons the company boasts 98% patient satisfaction in Germany. ColoAlert is also easy to use, which should be a big driver of adoption. Within five minutes your sample is collected and packaged and on the way to the lab. Patients receive a kit in the mail that includes instructions, a stool collector and a shipping label to return the kit to their local lab for testing. Patients receive the results in a few days. Mainz Biomed wants to bring its ColoAlert early cancer screening test to the U.S., and it is inking deals and readying clinical trials to achieve that. Its agreements with Quest Diagnostics put it one step closer. Stay tuned in 2025 – there may be lots more to come from Mainz Biomed on its path to commercializing ColoAlert in the U.S. and beyond. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 20, 2024 08:30 AM Eastern Standard Time

Image

PathAI Launches AIM-IHC Breast Panel on AISight® Platform to Streamline Breast Cancer Biomarker Quantification and Improve Pathologist Efficiency

PathAI

PathAI, a leader in AI-powered pathology solutions, today announced the launch of the AIM-IHC Breast Panel, a set pf advanced AI-assisted, algorithms designed to quantify critical breast cancer biomarkers—HER2, ER, PR, and Ki-67. Available now on the AISight® Image Management System (IMS), this comprehensive panel provides partners with accurate, consistent scoring, enhancing precision and streamlining workflow efficiency. Adding to the existing AIM-HER2 Breast solution, this consolidation of critical breast cancer biomarker algorithms into a single, pathologist-centric image management system directly addresses the need for standardized, reliable quantification assist tools to support pathologists. PathAI’s AIM-IHC Breast Panel is designed to address key challenges in breast cancer biomarker quantification, particularly the need for precise and reproducible assessment. The panel provides accurate, consistent, zero-click scoring for HER2, ER, PR, and Ki-67 directly from routine immunohistochemistry (IHC) images. With automated tissue segmentation and detection of on-slide controls, the panel classifies areas of invasive versus non-invasive cancer and provides overlays to support algorithmic scoring. This breast cancer-centric panel is designed for a pathologist-assist workflow, allowing users to better differentiate regions of interest, improve the accuracy of invasive cancer segmentation, and streamline tedious scoring processes. The AIM-IHC Breast Panel is the latest addition to PathAI's expanding suite of AI-powered solutions on the AISight® IMS. AISight serves as a central hub for managing pathology images, enabling seamless integration of various AI-driven tools for pathology labs. By centralizing workflows and offering a growing portfolio of applications, PathAI empowers pathologists and researchers to improve precision and efficiency, all within a unified, cloud-native platform. This continuous expansion of the AISight IMS and the full menu of AI applications available on the platform from PathAI as well as third-party vendors underscores PathAI’s commitment to providing comprehensive, reliable tools that enhance the field of pathology and ultimately, patient outcomes. “We are committed to advancing precision pathology with cutting-edge AI technology, empowering pathologists with the tools to make more accurate, consistent, and efficient assessments,” said Andrew Beck, CEO of PathAI. “The AIM-IHC Breast Panel is the latest step in our mission to enhance AI-powered scoring for key breast cancer biomarkers.” In addition, the AIM-IHC Breast Panel goes beyond HER2 by offering fast and accurate Ki-67 scoring, addressing the challenges of this emerging biomarker, which has traditionally been time-consuming and labor-intensive. Pathologists no longer need to spend significant time manually counting cells or rely on imprecise approximations. The panel’s automated features, such as classifying invasive cancer and generating percentage-based results for positive cancer cells, provide pathologists with the clarity needed to produce more accurate scoring. The introduction of the AIM-IHC Breast Panel marks a significant step in PathAI’s ongoing mission to enable precision pathology and empower pathologists with the latest AI-driven technologies. This release highlights PathAI’s commitment to improving workflow efficiency, speed, and assessment accuracy. As the AISight® Image Management System continues to expand with new solutions, pathologists gain access to a comprehensive suite of tools that streamline their workflow, accelerating decision-making and reducing time spent on manual tasks. With each of our new advancements, pathologists are better equipped to deliver precise, actionable insights for cancer diagnostic research. Footnotes AIM-IHC Breast Panel, AIM-HER2, AIM-ER, AIM-PR, and AIM-Ki-67 are for research use only. Not for use in diagnostic procedures. AISight is for Research Use Only in the US; AISight Dx is CE-IVD marked in Europe, UK and Switzerland. About PathAI PathAI is a global leader in AI-powered digital pathology solutions, dedicated to improving operational efficiency in pathology labs worldwide. Through its innovative technology and strategic partnerships, PathAI is shaping the future of medical diagnostics and advancing patient care across the globe. Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

December 09, 2024 10:00 AM Eastern Standard Time

UNOS and Donate Life America invite you to honor donors

United Network for Organ Sharing

The United Network for Organ Sharing (UNOS) and Donate Life America (DLA) invite the public to join the National Tree of Life virtual event to honor and remember this year’s organ, eye and tissue donors and their families. The National Tree of Life ceremony will take place on December 16 at 6:30 p.m. ET. The annual event honors the legacy of donors in each state who gave the gift of life in 2024 and celebrates the tens of thousands of lives they saved. The event will be live streamed on Donate Life America’s Facebook page. As part of this year’s ceremony, the winner of the annual Lisa Schaffner Community Advocate Award will be announced. The award recognizes those who go above and beyond to promote organ donation. The award is named after Lisa Schaffner, a powerful advocate of donation and transplant and former UNOS employee, who passed away in 2021. The ceremony will feature speakers from DLA, UNOS and the organ donation and transplant community, including: Jan Flanders, a tissue recipient and family member of an organ donor Sam Dey, a heart recipient Samuel and Susan Kirton, a double lung recipient and a caregiver Each year, the Tree of Life ceremony recognizes the lives and gifts of more than 20,000 organ donors – and tens of thousands of cornea and tissue donors – and their families, while also celebrating the lives of recipients across the country. Volunteers with connections to donation and transplant will honor donors from each state by hanging ornaments on the trees of life and lighting candles of remembrance. “The Tree of Life event is a moving reminder of the tremendous loss, bravery and joy that organ donation and transplant bring, and the ripple effect it has on each of us,” said Maureen McBride, Ph.D., CEO of UNOS. “We are thankful for those who have given the gift of life and for their courageous families.” “As we honor donors and donor families from this year during the National Tree of Life ceremony, we also recognize and celebrate the enduring legacy of lifesaving generosity of all donors and donor families who have given the gift of life in past years,” said David Fleming, DLA president and CEO. “We hope the Tree of Life ceremony helps provide community and solace.” Watch the event on the National Tree of Life Facebook event page: https://www.facebook.com/share/18T7djHSUJ/. For more information about organ, eye and tissue donation and how to register to be a donor, visit donatelife.net. About UNOS The United Network for Organ Sharing (UNOS) is a nonprofit organization that serves the organ donation and transplant system and broader public health community through its work developing new technologies and initiatives, conducting data-driven research and analysis, providing expert consulting services, advocating for patients, and being a leader in bringing communities together to save lives. About Donate Life America Donate Life America (DLA) is a 501(c)3 nonprofit organization leading its national partners and Donate Life State Teams to increase the number of donated organs, eyes and tissues available to save and heal lives. DLA owns, manages and promotes Donate Life℠, the national logo and brand for the cause of donation; motivates the public to register as organ, eye and tissue donors; provides education about living donation; owns and manages the National Donate Life Registry at RegisterMe.org and develops and executes effective multi-media campaigns to promote donation. Contact Details United Network for Organ Sharing Anne Paschke anne.paschke@unos.org Donate Life America Hilary Kleine media@donatelife.net Company Website https://unos.org

December 09, 2024 09:40 AM Eastern Standard Time

Image

Teambuilder Receives Patent for Predictive Staff Scheduling in Healthcare

TeamBuilder

TeamBuilder has been granted Patent No. 12148523 for its predictive staff scheduling technology. The patent covers TeamBuilder’s innovative approach of weaving patient volume, workflow and employee availability and characteristics into an easy-to-use interface that managers can use to make optimal scheduling decisions. This achievement underscores TeamBuilder’s commitment to leveraging data-driven solutions to improve staffing efficiency, reduce costs, and enhance patient care. “Securing a patent for our predictive staff scheduling technology is a significant milestone for TeamBuilder, confirming the innovation behind our solution,” said David Howard, Founder and CEO of TeamBuilder. “Our technology addresses the complex staffing challenges healthcare providers face today, offering a smarter, more efficient way to manage workforce needs while improving both staff and patient outcomes.” Staff scheduling in healthcare is inherently complex, with fluctuating patient demand, varying specialty needs, multiple locations, and diverse staff preferences. Despite this, many healthcare organizations continue to rely on staffing ratios and manual scheduling systems, such as paper or Excel-based methods, which often lead to overstaffing, administrative inefficiencies, and a lack of visibility into key operational metrics. How TeamBuilder Works: Schedule Optimization: Develops the most efficient schedule by balancing patient demand, staff availability, workload, and clinic constraints, minimizing gaps in coverage. Staff Allocation: Focuses on analyzing staff availability and workload to predict the optimal number of staff needed for each shift, ensuring the right coverage in alignment with patient demand. Operational Visibility: Provides real-time insights into clinic operations, resource allocation, and clinic-to-clinic comparisons, enabling data-driven staffing adjustments and resource planning. Performance Tracking: Tracks key metrics such as resource cost per visit and peer benchmarking to evaluate and enhance operational efficiency. “The shift toward data-driven predictive scheduling is no longer optional—it’s essential,” says Niel Oscarson, Research Director at KLAS. “Healthcare organizations that can accurately forecast staffing needs will see improvements in both operational efficiency and patient care quality. Our conversations with TeamBuilder customers indicate that Teambuilder is making a significant impact with its patented technology, creating new and significant efficiencies in workforce management. Additionally, TeamBuilder’s focus on the ambulatory care space addresses a critical area of need.” TeamBuilder’s patented staff scheduling technology not only transforms workforce management but also drives tangible, measurable improvements. Healthcare organizations have seen an 11% improvement in access to care and payroll reductions of 9-14% through optimized staffing. The technology also enhances communication and reduces the time required to create and manage schedules, streamlining operations. These outcomes highlight TeamBuilder’s impact on improving efficiency, reducing costs, and enhancing patient care. About TeamBuilder: TeamBuilder is an innovator in healthcare workforce management, offering a smart scheduling solution powered by patented predictive technology. By combining data science with intuitive scheduling interface, TeamBuilder helps healthcare organizations optimize staffing, reduce costs, and improve patient care. The platform’s focus on predictive scheduling is reshaping how healthcare facilities approach workforce management, ultimately benefiting both staff and patients. For more information about TeamBuilder, visit www.teambuilder.io or contact Mea Parikh About KLAS Research: KLAS Research is a leading healthcare research firm that provides insights into healthcare technology solutions. Their reports help organizations make informed decisions by offering accurate, independent evaluations of products and services. Contact Details Mea Parikh Marketing and Business Development mea@teambuilder.io Company Website https://teambuilder.io/

December 09, 2024 08:30 AM Eastern Standard Time

Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit

Benzinga

By Meg Flippin, Benzinga RedHill Biopharma Ltd. (NASDAQ: RDHL), a specialty biopharmaceutical company, won a significant legal and financial victory, announcing a summary judgment in its favor and an award of about $8 million plus costs in its New York Supreme Court case against Kukbo Co. Ltd. o f South Korea. RedHill Biopharma sued Kukbo over a breach of contract related to opaganib, the company’s first-in-class orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple indications. Opaganib has several U.S. government and academic collaborations in place for development for radiation and chemical exposure indications such as Acute Radiation Syndrome (ARS), a phase 2/3 program for hospitalized COVID-19, and a phase 2 program in oncology. Breach Of Contract At The Heart Of Lawsuit The lawsuit stemmed from Kukbo’s failure to make agreed payments to RedHill pursuant to a subscription agreement signed on Oct. 25, 2021, and a subsequent exclusive license agreement inked on March 14, 2022. The two were working to develop opaganib for COVID. The Supreme Court of the State of New York ruled in favor of RedHill Biopharma and, in a summary judgment, ordered Kukbo to pay $8 million, consisting of $6.5 million plus interest amounting to approximately $1.5 million, plus costs. The court dismissed Kukbo’s counterclaims. Kukbo has a right to seek an appeal of the judgment, which may or may not be granted. RedHill intends to pursue its attorneys' fees and collection of the judgment. "RedHill thanks the Court for this crystal-clear judgment, affirming the company's just position from the beginning of the relationship and in making correct provision for full reparation for the contractual breaches,” said Dror Ben-Asher, RedHill’s CEO. Once collected, the summary judgment will give RedHill more cash to develop its pipeline and eliminates a potential overhang on the stock. TipRanks called the ruling a “significant financial victory,” one that highlights RedHill’s adherence to contractual agreements. TipRanks said the end to litigation could boost investor confidence in the company. The positive ruling comes as RedHill Biopharma is making progress in developing opaganib for infectious diseases such as Ebola. Recently, RedHill announced that the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA), a center of the Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR), had selected opaganib for development to treat exposure to Ebola virus disease (EBOV). Under the cost-sharing agreement with BARDA, BARDA will provide partial funding for RedHill to further advance opaganib to mitigate infections and contain EBOV outbreaks. In an in vivo EBOV study with the United States Army Medical Research Institute of Infectious Diseases, RedHill Biopharma said opaganib delivered a statistically significant increase in patient survival time when given at 150 mg/kg twice a day. RedHill Biopharma said it’s the first host-directed molecule to show activity in EBOV. Several other U.S. government countermeasures and pandemic preparedness programs have also selected opaganib for evaluation for multiple indications, reports the company. With litigation in the rearview mirror and RedHill Biopharma making progress in developing opaganib, interested investors may want to pay attention to what’s next from this specialty biopharmaceutical company. Featured photo by Scott Graham on Unsplash. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 09, 2024 08:00 AM Eastern Standard Time

Image

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Benzinga

By Joshua Enomoto, Benzinga In the rapidly evolving medical technology sector, diabetes management specialist Glucotrack Inc. (NASDAQ: GCTK) aims to disrupt the present care framework for the benefit of patients. Thanks to its Continuous Blood Glucose Monitor (CBGM), millions of people affected by the disease may be able to access reliable, non-intrusive glucose monitoring. Fundamentally, what distinguishes Glucotrack from its rivals is the combination of real-time accuracy without the delay associated with conventional continuous glucose monitoring systems. In addition, the medical tech specialist offers an implantable format, eliminating the hassles associated with external wearables. Even better, the system’s long sensor life facilitates convenience. To further validate the feasibility of Glucotrack’s product under real-world conditions – and help bring the CBGM system closer to regulatory approval and commercialization – the company has recently announced the commencement of patient enrollment for its short-term human clinical study. Clinical Study Shines Spotlight On Glucotrack’s CBGM Technology Scheduled to be conducted at the Heart Institute (InCor) of the Clinical Hospital of the University of São Paulo – one of the most renowned cardiology hospitals in Brazil and across Latin America – the feasibility study will focus on the capabilities of Glucotrack’s CBGM. A long-term implantable device, the CBGM features no on-body external component. Furthermore, the system is designed to provide three years of continuous, accurate blood glucose monitoring. However, the core attribute of the device is that it measures glucose levels directly from the blood as opposed to interstitial fluid, as is common among competing systems. Blood glucose measurement is the gold standard for glucose measurement. Thus, these capabilities could enable more convenient and less intrusive diabetes management. Principal Investigator Dr. Alexandre Abizaid, MD, PhD will spearhead the study. As the director of Interventional Cardiology at the Heart Institute in São Paulo, Brazil and a visiting professor of medicine at Columbia University Medical Center in New York City, Dr. Abizaid represents one of the leading experts in interventional cardiology. So, why is a diabetes study being performed by an interventional cardiologist? The CBGM is similar in size and form to implantable devices in the cardiovascular space. Thus, the placement procedure is recognizable and widely performed by interventional cardiologists as an outpatient procedure, under local anesthesia in a cardiac catheterization, or cath, lab. The placement procedure takes approximately 20 minutes and only requires a small, half inch incision. Not to mention, diabetes can, and often does, lead to heart disease; people with diabetes are two to four times more likely than others to develop cardiovascular disease. So, cardiologists are becoming more and more involved in patient care for people with diabetes. Notably, the five-day study will include patients suffering from both type 1 and type 2 diabetes. First, clinical researchers will apply the CBGM sensor intravascularly (inside the blood vessel) in the study participants. Second, Glucotrack says the participants will be monitored based on the following protocol: Observation: During this period, researchers will leverage the CBGM technology to monitor blood glucose levels in real time. This observation will provide data on how blood glucose levels fluctuate under various conditions. Glucose challenges: Participants will be given fixed meal challenges, during which their blood glucose levels will be monitored to assess how their glucose responds to different types of food. Comparative analysis: In addition to data collection, the study will focus on the accuracy and performance of the CBGM in measuring blood glucose levels compared to conventional glucose monitoring mechanisms. Advancing Positive Disruption In Diabetes Management With the announcement of the clinical study – with results expected to be available within six to eight weeks – Glucotrack has moved one step closer to positively disrupting the current paradigm in diabetes management. According to Grand View Research, the global diabetes devices market size is large, reaching a valuation of $30.31 billion last year. “Following the success of our preclinical program, we are pleased to reach this key milestone in the development of our novel CBGM,” said Paul V. Goode, PhD, president and CEO of Glucotrack. “We believe this groundbreaking early feasibility study will demonstrate the potential for our real-time continuous blood glucose monitor to offer a truly differentiated and less burdensome approach to glucose monitoring for people with diabetes.” Forging a path toward significantly reducing the friction and pain points of diabetes care epitomizes the essence of Glucotrack’s device. What separates the enterprise from the competition is the integration of glucose monitoring accuracy, speed and convenience — elements that are often found in disparate corporate silos, the company argues. For instance, Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) both have a strong presence in the continuous glucose monitoring (CGM) market, but their systems require frequent sensor changes, usually every 10 to 15 days, depending on the system. Reports show that some of these adhesive patch systems also suffer from wearability challenges. In sharp contrast, Glucotrack says it addresses the shortcomings of conventional CGM devices while elevating the standard of care. Adding to the long list of advantages, the company’s CBGM system also requires minimal calibration. Revolutionizing Diabetes Care With Cutting-Edge Glucose Monitoring Glucotrack is striving to push boundaries in diabetes care with its approach to continuous blood glucose monitoring. With the launch of its clinical study and a focus on delivering real-time accuracy and convenience through its implantable device, the company hopes to address critical gaps in the current market. As Glucotrack advances toward regulatory approval, its technology holds the potential to redefine how diabetes is managed, hopefully offering patients a more seamless and less burdensome solution. Featured photo by Deon Collison on Unsplash This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 05, 2024 10:00 AM Eastern Standard Time

Image

Classiq and AQT Partner to Deliver Seamless Ion-Trap Integration to Tackle Real-World Challenges

Classiq Technologies

Classiq Technologie s, a leader in quantum computing software, and Alpine Quantum Technologies (AQT), a global pioneer in ion-trap quantum computing, today announced a strategic partnership to deliver seamless integration between Classiq’s enterprise-grade quantum algorithm design platform and AQT’s state-of-the-art ion-trap quantum computers. By combining the Classiq platform’s ability to develop sophisticated, scalable quantum circuit implementations with AQT’s award-winning ion-trap hardware, the partnership offers customers expanded options for their quantum computing activities. It enables both enterprises and researchers to tackle complex computational challenges with greater efficiency. Through this partnership, users gain access to a unified workflow that bridges Classiq’s innovative, hardware-aware software tools with AQT’s advanced quantum hardware. Classiq’s platform automates the design, optimization and implementation of quantum algorithms, enabling users to develop, debug and execute sophisticated quantum applications. The integration with AQT’s precision ion-trap systems ensures high-performance operation, catering to the needs of enterprise teams and academic researchers alike. A Shared Vision for Quantum Innovation “We’re dedicated to offering our users the broadest set of quantum computing hardware options,” said Nir Minerbi, co-founder and CEO of Classiq. “The integration of our quantum algorithm design platform with AQT’s advanced ion-trap systems provides a compelling opportunity for enterprises and researchers to implement and run their quantum circuits with ease, scalability and reliability.” “This partnership brings together the best of quantum software and ion-trap hardware, allowing innovation to thrive,” said Dr. Thomas Monz, CEO of AQT. “By integrating with Classiq, we are making it simpler than ever for enterprises and researchers to harness the potential of ion-trap quantum computing for real-world challenges.” Building a Quantum Future This collaboration advances quantum readiness by fostering interoperability within the quantum ecosystem. By uniting their expertise in software and hardware, Classiq and AQT are paving the way for further innovation, benchmarking and the exploration of new quantum implementations. The partnership also opens doors for future collaboration opportunities, such as integrations with high-performance computing (HPC) environments. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking you from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X or YouTube, and visit the Slack community and www.classiq.io to learn more. About AQT Alpine Quantum Technologies (AQT) is a global leader in ion-trap quantum computing, offering high-fidelity systems designed for real-world scalability and applications. Based in Innsbruck, Austria, AQT builds on decades of academic excellence to provide industry-leading solutions for enterprise quantum computing. Follow AQT on LinkedIn and X. For more information about AQT, please visit: www.aqt.eu. Contact Details Rainier Communications Michelle Allard McMahon on behalf of Classiq classiqPR@rainierco.com AQT Franz Domig, Marketing & Communication Director +43 720 262627126 franz.domig@aqt.eu Company Website http://www.classiq.io/

December 05, 2024 08:00 AM Eastern Standard Time

YourFMO Enhances Agent ACA Marketplace Sales Experience

AmeriLife

YourFMO.com, a non-government agent resource site built for today’s valued health and life insurance agent, today announced the integration of Agility Insurance Services and its MyAdmin by Agility platform to support Affordable Care Act (ACA) plan sales. This exclusive offering is now available to YourFMO-contracted, licensed agents for the ACA Open Enrollment Period and beyond, with a comprehensive, real-time, and turnkey solution. As a result, this integration provides YourFMO-affiliated insurance agents with access to 20 contracted carriers offering ACA plans through a digitized process that eliminates paperwork, streamlines enrollments, and is designed to help increase productivity and efficiency. The platform serves as a one-stop shop, empowering agents to successfully manage their clients' ACA needs and track commissions seamlessly. "We are thrilled to integrate this innovative technology offered by Agility Insurance to enhance YourFMO’s comprehensive suite of agent resources," said JC Moreno, National Director of ACA at AmeriLife. "For ACA sales, this platform is a game-changer that simplifies enrollment and provides our agents with complete training guides powered by a robust CRM system." Agility Insurance Services offers its comprehensive platform for everything related to ACA sales. MyAdmin by Agility enables agents to manage client relationships, track interactions, and organize their sales efforts more effectively. This integration ensures that YourFMO contracted and licensed agents have all the necessary tools in one place, providing security and simplifying their workflow. Key features of this exclusive offering include: Digitization: Automates the enrollment experience, resulting in speed and efficiency. Real-time solutions: Instant access to plan details, quotes, and registration status. Turnkey solution: A single platform for everything ACA sales-related, from carrier plans to commission tracking. Comprehensive training: Complete guides to ensure agents are well-equipped to navigate the platform and ACA plans. YourFMO-affiliated agents can now leverage this powerful platform to better serve their clients and maximize their opportunities during the Open Enrollment Period and beyond. To sign up or learn more, please visit YourFMO.com. ### About YourFMO.com YourFMO is a non-government agent resource platform designed and managed by AmeriLife that is built to make selling insurance easy for our valued agents. YourFMO.com understands the need for the right technology, tools, and training for our independent agent partners to be successful in today’s health and life insurance marketplace. Contact us today to see how this suite of tools will benefit your business. For more information, visit YourFMO.com. About Agility Insurance Agility Insurance Services is an agency focused on equipping health insurance agents with all the tools they need to make health insurance available to anyone who might need it – from individuals to small business owners. Agility’s sales professionals specialize in health insurance marketing and contracting, and they provide ample resources to agents, ensuring their ability to better serve customers. Whether through assisting an individual or small business owners, Agility agents are dedicated to helping their customers find the best coverage possible. Learn more here. Contact Details YourFMO Jeff Maldonado media@yourfmo.com Luminos Creative Frank Vasquez fvasquez@luminoscreative.com Company Website https://amerilife.com/

December 03, 2024 10:30 AM Eastern Standard Time

1 2 3 4 5 ... 301